On Friday, Shares of QUALCOMM Incorporated (NASDAQ:QCOM), gained 1.41% to $62.73.
QUALCOMM Incorporated, declared a quarterly cash dividend of $0.48 per common share, payable on September 23, 2015, to stockholders of record at the close of business on September 2, 2015.
QUALCOMM Incorporated designs, develops, manufactures, and markets digital communications products and services in China, South Korea, Taiwan, and the United States. The company operates through three segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Planned Initiatives (QSI).
Shares of Unilever NV (NYSE:UN), inclined 5.13% to $43.87, during its last trading session.
Unilever declared that it has signed a contract to acquire Murad, a leading clinical skincare brand. This follows the recent acquisitions of Dermalogica, Kate Somerville and REN, which jointly position Unilever as a key player in the personal care prestige segment.
Paul Polman, Unilever CEO, said: “We are delighted to welcome Murad to our portfolio of Prestige personal care brands. As an expert ‘Doctor brand’, Murad offers products in a differentiated clinical and holistic well-being segment. It has a loyal following that gives it excellent potential for expansion, and wonderfully complements the brands recently attained. We look forward to working with Dr Murad and his team to continue to grow the brand.”
Dr Howard Murad added: “We’ve always looked for opportunities to reach more people with our message of Inclusive Health and to touch more lives with our targeted, high-performance products. With Unilever, we can broaden our reach and significantly grow our brand while remaining faithful to the founding principles of Murad. There is a very bright path ahead and I am excited to work with Unilever to share our products with the world—together we can inspire every person that the Murad brand touches to live life beautifully.”
Unilever N.V. operates as a fast-moving consumer goods company in the Americas, Europe, Asia, Australasia, Africa, the Middle East, Turkey, Russia, Ukraine, and Belarus. The company operates through Personal Care, Foods, Refreshment, and Home Care segments.
Finally, Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), ended its last trade with 4.27% gain, and closed at $4.88.
Catalyst Pharmaceuticals, declared the appointment of Gary Ingenito, M.D., Ph.D, as Chief Medical Officer. Dr. Ingenito has more than 25 years of experience leading pharmaceutical development for drugs and biologics. In this new role, he will oversee all clinical development programs, medical affairs, regulatory and other related functions. Dr. Ingenito will report to Dr. Steven Miller, Catalyst’s Chief Operating Officer and Chief Scientific Officer. Following Dr. Ingenito’s joining Catalyst, the current Chief Medical Officer, Charles Gorodetzky, M.D., Ph.D, will continue to serve as a consultant to the company.
“I am happy to welcome Gary to our team. Gary brings broad experience in leading successful development efforts for medicines across various disease states within both biotech and big pharma. Gary is the perfect fit for Catalyst as our product development programs continue to advance. As we near our NDA submission for Firdapse®, we look forward to Gary’s contributions to expanding the use of Firdapse® for other indications, furthering the development of CPP-115, and potentially expanding our development pipeline to comprise new drugs for other rare diseases.” said Patrick J. McEnany, Chief Executive Officer of Catalyst. He continued “I would also like to thank Chuck Gorodetzky for his noteworthy contributions to Catalyst over the past 10 years and for his commitment to bringing new therapies to people suffering from unmet medical needs.”
Catalyst Pharmaceuticals, Inc., a development-stage biopharmaceutical company, focuses on the development and commercialization of prescription drugs targeting rare (orphan) neurological diseases and disorders.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
